ClinicalTrials.gg
CompletedNCT02688647Updated Sep 8, 2022Results posted

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of Belumosudil and BSC in Idiopathic Pulmonary Fibrosis, sponsored by Kadmon Corporation, LLC. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-08.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
88th of 188
76 · median 61
Started
2016
with 10 others
Phase 2
82 of 236
13 open now
Registered
99th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 88th largest by enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2016, is one of 82 in phase 2, and was the 99th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized female subjects with Idiopathic Pulmonary Fibrosis (IPF). The primary objectives are to evaluate the:

  • Change in Forced Vital Capacity (FVC) from baseline to 24 weeks after dosing with belumosudil 400 mg PO QD in subjects with IPF compared to BSC
  • Safety and tolerability of belumosudil 400 mg PO QD when administered for 24 weeks to subjects with IPF compared to BSC
Read the detailed description

Study KD025-207 is a Phase 2, randomized, 2-part, open-label, crossover study in subjects with IPF.

The purpose of the study is to evaluate the safety, tolerability, and activity of 400 mg of belumosudil administered orally (PO) every day (QD) compared to Best Standard of Care (BSC) in subjects with IPF who have previously been treated with or declined treatment with pirfenidone or nintedanib.

The primary objectives are to evaluate the change in Forced Vital Capacity (FVC), and the safety and tolerability from baseline to 24 weeks in subjects with IPF after dosing with belumosudil 400 mg PO QD compared to BSC.

Part 1: Randomized, Open-label for 24 Weeks

Approximately 81 eligible subjects with IPF are to be enrolled, in 10 to 15 sites, and randomized in a 2:1 ratio (belumosudil:BSC) to 1 of the following 2 groups:

  • Belumosudil-R (Investigational Group): Belumosudil 400 mg PO QD for 24 weeks
  • BSC-R (Control Group): BSC for 24 weeks

The study plan is for 54 subjects to be entered into the Belumosudil-R Treatment Group and 27 subjects into the BSC-R Treatment Group. This sample size provides over 90% power at the 2-sided 0.05 significance level to detect a 20% difference between treatment groups at 24 weeks in percentage change from baseline in FVC assuming a standard deviation (SD) in percentage change from baseline in FVC of 17%. The sample size of 54 subjects receiving belumosudil provides over 90% probability of ≥ 1 subject in the study experiencing an AE that had an underlying rate of ≥ 5%.

Part 2: Continuation of Belumosudil Therapy or Crossover to Belumosudil Therapy Subjects in the Belumosudil-R group who complete 24 weeks of treatment with belumosudil 400 mg PO QD have the option of continuing therapy with belumosudil 400 mg PO QD up to an additional 72 weeks if there are no safety signals and if clinical progress continues. No subject in the Belumosudil-R group is to be permitted to receive therapy with belumosudil greater than a total of 96 weeks.

Subjects in control group BSC-R who complete 24 weeks of BSC have the option of crossing over to therapy with belumosudil 400 mg PO QD for up to 96 weeks if there are no safety signals and if clinical progress continues. No subject in control group BSC-R is to be permitted to receive belumosudil 400 mg PO QD therapy greater than 96 weeks.

Follow-up Period:

Follow-up Visits are to occur 30 days (± 3 days) after the last dose of belumosudil during which subjects are to undergo safety assessments. (A Follow-up Visit is not necessary for subjects receiving BSC.)

Duration of Study for Individual Subjects:

  1. Subjects randomized to belumosudil: total up to 104 weeks (4-week screening, 96-week treatment with belumosudil, and 4-week follow-up)
  2. Subject randomized to BSC: total up to 128 weeks (4-week screening; up to 24-week treatment with BSC, 96-week treatment with belumosudil, and 4-week follow-up)

Efficacy Assessments

  • FVC
  • FVC% Predicted
  • 6-minute Walking Distance (6MWD)
  • Diffusing Capacity of Carbon Monoxide (DLCO)
  • Lung Fibrosis (by HRCT and Radiologist's Visual Assessments)
  • Time to Acute Exacerbation
  • Time to Progression of IPF
  • Time to Respiratory-related Hospitalization
  • Time to Respiratory-related Death
  • St. Georges Respiratory Questionnaire (SGRQ)

Biomarker Assessments

  • Matrix Metalloproteinase-7 (MMP7)
  • Chemokine Ligand 18 (CCL18)
  • Surfactant Protein-D (SPD)

Safety Assessments

  • Adverse event (AE)
  • Serious adverse event (SAE)
  • Physical examination (PE)
  • Vital signs (VS)
  • Clinical laboratory evaluations (hematology, chemistry, and urinalysis)
  • Electrocardiogram (ECG)
  • Reason for treatment discontinuation due to toxicity

Analyses

Efficacy and safety are to be analyzed at the end of Part 1 (Week 24) and for the Entire Treatment Period (Parts 1 and 2). Analyses of study subjects are to be grouped and defined as follows:

  • Belumosudil-R: subjects randomized to belumosudil
  • BSC-R: subjects randomized to BSC
  • Belumosudil-WC: subjects randomized to belumosudil plus subjects randomized to BSC and who cross over to treatment with belumosudil
  • BSC-NC: subjects randomized to BSC and who cross over to treatment with belumosudil but have data censored by the date of crossover
03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Pulmonary Fibrosis
  • Fibrosis
  • Idiopathic Interstitial Pneumonias
  • Lung Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject had to meet all of the following criteria to be eligible for the study:

  1. Adult male and /surgically sterilized female subjects at least 18 years of age (if female, was surgically sterilized [i.e., total hysterectomy, or bilateral salpingo-oophorectomy]).
  2. Able to provide written before the performance of any study specific procedures.
  3. IPF diagnosis within 5 years before study entry, proven according to the American Thoracic Society/European Respiratory Society consensus conference criteria, with surgical lung . In the absence of a surgical lung biopsy, high-resolution computerized tomography (HRCT) consistent with usual interstitial pneumonitis.
  4. Resting state pulse oximeter oxygen saturation (SpO2) ≥ 88% with or without supplemental oxygen, Forced Vital Capacity % (FVC%) ≥ 50% normal predicted value, and diffusing capcity (in the lung) of carbon monoxide (DLCO) ≥ 30% normal predicted value at baseline.
  5. Men with partners of willing to use 2 medically acceptable methods of during the trial and for 3 months after the last dose of study drug. Effective birth control includes:

    1. Intrauterine device plus 1 barrier method
    2. Stable doses of hormonal contraception for ≥ 3 months (e.g., oral, injectible, implant, transdermal) plus 1 barrier method
    3. 2 barrier methods. Effective barrier methods were male or female condoms, diaphragms, and spermicides (creams or gels containing a chemical to kill sperm)
    4. Vasectomy.
  6. Have adequate bone marrow function:

    1. > 1500/mm\^3
    2. (Hb) > 9.0 g/L
    3. > 100,000/mm\^3
  7. Willing to complete all study measurements and assessments in compliance with protocol
  8. Had either received pirfenidone and/or nintedanib or offered both treatments (with last dose administered at least 1 month before the expected start of study drug dosing). If either or both pirfenidone and nintedanib treatment had not been given, then documentation that the subject was offered both treatments must have been documented.

Exclusion criteria

Exclusion Criteria:

A subject who met any of the following criteria was ineligible for the study:

  1. Interstitial lung disease caused by conditions other than IPF
  2. Severe concomitant illness limiting (\< 1 year)
  3. DLCO \< 30% predicted
  4. Residual volume (RV) ≥ 120% predicted
  5. Obstructive lung disease: (FEV1/FVC ratio \< 0.70)
  6. Documented sustained improvement of the subject's IPF condition up to 12 months before study entry with or without IPF-specific therapy
  7. Pulmonary infection or upper respiratory tract infection (URTI) within 4 weeks before study entry
  8. Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements (e.g., pulmonary function tests [PFTs])
  9. Chronic heart failure with Class III/IV or known \< 25%
  10. Moderate to severe hepatic impairment (i.e., Class B or C)
  11. Estimated \< 30 mL/min
  12. (AST) and/or alanine aminotransferase (ALT) > 2.0 * (ULN)
  13. \< 75% of the lower limit of normal
  14. Systolic blood pressure \< 100 mmHg
  15. Pregnant or breastfeeding female subject
  16. Men whose partner is pregnant or breastfeeding
  17. Current drug or alcohol dependence
  18. Chronic treatment with the following drugs within 4 weeks of study entry and during the study:

    1. or cytotoxic drugs including cyclophosphamide and azathioprine
    2. Antifibrotic drugs including pirfenidone, nintedanib, D-penicillamine, colchicine, tumor necrosis factor-alpha blockers, imatinib, and interferon-γ
    3. Chronic use of N-acetylcysteine prescribed for IPF (> 600 mg/day)
    4. Oral anticoagulants prescribed for IPF
  19. Treatment with endothelin receptor antagonists within 4 weeks before study entry
  20. Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)
  21. Previous exposure to belumosudil or known allergy/sensitivity to belumosudil or any other Rho-associated protein kinase 2 (ROCK2) inhibitor
  22. Planned treatment or treatment with another drug within 4 weeks before study entry
  23. Taking a medication with the potential for prolongation
  24. Taking a drug sensitive substrate of CYP enzymes
  25. Taking a strong inducer of
  26. Had consumed an herbal medication (e.g., St. John's Wort) or grapefruit/grapefruit juice within 14 days prior to the Week 1 Day 1 visit
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Belumosudil-R

    Subjects receive two 200 mg tablets of belumosudil (400 mg) PO QD for 24 weeks. Subjects may also continue treatment with belumosudil 400 mg PO QD after 24 weeks. No subject may receive more than 96 weeks of treatment with belumosudil

    Drug: Belumosudil

  • Active comparator
    BSC-R

    Subjects receive best supportive care as determined by the physician. Subjects may later crossover to treatment with belumosudil 400 mg PO QD. No subject may receive more than 96 weeks of treatment with belumosudil.

    Other: BSC

Interventions

  • Also known as: KD025, SLx-2119

  • OtherBSC

    Treatment/drug as determined by each subject's prescribing physician

    Also known as: Best standard of care

06

What researchers measure

Primary outcomes

  1. Efficacy: Mean Changes in FVC From Baseline to Week 24

    Changes in the mean Forced Vital Capacity (FVC) from baseline at Week 24. Normal FVC-- Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy females 20 to 60 years: 3.25 to 3.75 L

    Time frame: 24 weeks

  2. Efficacy: Mean Changes in FVC% Predicted From Baseline at Week 24

    Changes in the mean Forced Vital Capacity (FVC)% Predicted from baseline at Week 24. Normal FVC%: 80% to 120%

    Time frame: 24 weeks

  3. Safety: Percentages of Subjects With Non-serious TEAEs and Relationship to Study Treatment

    Percentage of subjects with non-serious TEAEs by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Severity of TEAEs were measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 22.1 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal).

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil. Subjects randomized to BSC had the option of crossing over at 24 weeks.

  4. Safety: Percentages of Subjects With SAEs Related to Study Treatment

    Percentage of subjects with serious TEAEs by relationship to treatment with belumosudil and/or BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil. Subjects randomized to BSC and crossing over also up to 24 weeks of BSC.

  5. Safety: Percentages of Subjects With TEAEs Leading to Discontinuation of Treatment With Belumosudil

    Percentage of subjects with treatment-emergent adverse events (TEAEs) leading to subjects discontinuing from treatment. Investigators assessed whether TEAEs leading to discontinuation were related to study drug (possibly, probably, or definitely), belumosudil 400 mg PO QD.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil

  6. Safety: Percentages of Subjects With Deaths Related to Study Treatment

    Percentage of subjects with deaths by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.

    Time frame: Up to 96 weeks (Weeks 24, 8, and 96) of treatment with belumosudil. Subjects randomized to BSC also had the option of crossing over to treatment with belumosudil at 24 weeks.

Secondary outcomes

  1. Efficacy: Mean Changes in FVC From Baseline at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--

    Changes in the mean Forced Vital Capacities (FVC) at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. Normal FVC--Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy famles 20 to 60 years: 3.25 to 3.75 L GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I Index = 0 to 3 points * Stage II Index= 4 to 5 points * Stage III Index = 6 to 8 points

    Time frame: 24 weeks

  2. Efficacy: Mean Changes in FVC From Baseline at Week 48, Week 96, and EOT

    Changes in the mean Forced Vital Capacity (FVC) from baseline at Weeks 48 and 96, and End-of-Treatment (EOT) Normal FVC: Healthy males 20 to 60 years: 4.75 to 5.25 L; healthy females 20 to 60 years: 3.25 to 3.75 L

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  3. Efficacy: Mean Change in Mean FEV1/FVC Ratio From Baseline at Weeks 24, 48, and 96 and EOT

    Change in the mean ratio of Forced Expiratory Volume in 1 Second (FEV1) divided by the Forced Vital Capacity (FVC) at Week 24, Week 48, Week 96, and End-of-Treatment (EOT) Normal FEV1: 80% to 120% FEV1/FVC = Within 5% of predicted ratio

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  4. Efficacy: Mean Changes in FVC% Predicted at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--

    Changes in the mean Forced Vital Capacities (FVC)% Predicted at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I = 0 to 3 points * Stage II = 4 to 5 points * Stage III = 6 to 8 points

    Time frame: 24 weeks

  5. Efficacy: Percentages of Subjects With Decrease ≥ 5% in FVC% Predicted From Baseline at Weeks 24, 48, and 96

    Percentage of subjects exhibiting at least a 5% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  6. Efficacy: Percentage of Subjects With Decrease ≥ 10% in FVC% Predicted at Weeks 24, 48, and 96

    Percentage of subjects who exhibited at least a 10% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  7. Efficacy: Mean Change in 6MWD at Weeks 24, 48, and 96

    The mean change in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, to Week 48, and to Week 96. Positive change = improvement; negative change = worsening

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  8. Efficacy: Percentages of Subjects With ≥ 50 Meter Improvement in 6MWD at Weeks 24, 48, and 96

    The percentage of subjects who have at least a 50 meter improvement in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, Week 48, and Week 96.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  9. Efficacy: Mean Changes in DLCO (%) at Weeks 24, 48, and 96

    The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  10. Efficacy: Percentages of Subjects With Change From Baseline in DLCO (%) ≤ -15% at Weeks 24, 48, and 96

    Percentage of the number of subjects who exhibit less than a -15% decrease in diffusing capacity of carbon monoxide (DLCO), measured as % from baseline at Week 24, Week 48, and Week 96 The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  11. Efficacy: Mean Changes in Total Lung Fibrosis Score, by HRCT, From Baseline at Weeks 24, 48, and 96

    The change in Total Lung Fibrosis mean score from baseline at Weeks 24, 48, and 96. Measurements using quantitative high-resolution computerized tomography (HRCT) and include (1) extent of fibrotic abnormality; (2) fibrosis score; (3) ground glass opacity; (4) honeycombing score; (5) kurtosis of lung voxel intensity; (6) skewness of lung voxel intensity; (7) standard deviation of voxel; (8) CT total lung volume; (9) normal lung; (10) reticular score; and (11) evaluation of change on sequential scans. The Quantitative Lung Fibrosis (QLF) score measures the extent of reticular patterns with architectural distortion due to fibrosis using a support vector machine classifier. Range: 0 to 100. Higher scores imply greater impairment.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  12. Efficacy: Categorical Changes in Lung Fibrosis as Observed by Sequential Scans of Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96

    The categorical changes of lung fibrosis using subjective visual assessments by radiologists from sequential scans at baseline, Week 24, Week 48, and Week 96. Changes were categorized as: (1) much better; (2) slightly better; (3) same; (4) slightly worse; and (5) much worse. This categorization is simplified as Better (Much or Slightly); Same; and Worse (Slightly or Much).

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  13. Efficacy: Changes in Mean DTA Lung Fibrosis Score, by Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96

    The change in Data-driven Texture Analysis (DTA) Lung Fibrosis mean score using sequential scans from Radiologist's Visual Reads from baseline to Weeks 24, 48, and 96. The change in DTA Lung Fibrosis mean score was measured using sequential scans from Radiologist's Visual Reads from baseline at Weeks 24, 48, and 96. DTA fibrosis score was computed as the number of Region of Interests (ROIs) classified as fibrotic divided by the total number of ROIs sampled from the lung segmentation volume. The DTA fibrosis score ranged from 0 - 100%, where higher scores indicated worsening of disease.

    Time frame: Up to 96 Weeks (Weeks 24, 48, and 96)

  14. Efficacy: Event-free Probability of Acute Exacerbation of IPF

    Acute exacerbation of IPF was defined by the following symptoms within 1 month that could not be explained by other reasons: (1) aggravated dyspnea; (2) newly discovered chest interstitial lung abnormality (by radiograph or HRCT); (3) SpO2 decrease to \< 88%. Acute exacerbation was diagnosed if Items #1 and #2 were present or if Items #1 and #3 were present and the following AEs did not occur: (A) any AE with the Preferred Term containing the word "infection" or "cardiac failure"; (B) pulmonary embolism; (C) pneumothorax.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  15. Efficacy: Event-free Probability of Progression of IPF

    Progression of IPF exacerbation was defined as the probability of a subject exhibiting IPF time from baseline to any of the following: (1) probability of first respiratory-related hospitalization; (2) probability of respiratory-related death; absolute decline in FVC% Predicted value of ≥ 10% vs. FVC %; probability of predicted value recorded at baseline; and (4) probability of absolute decline in DLCO, adjusted for hemoglobin (Hb), Percent of predicted value of ≥ 15% vs. DLCO at baseline. Subjects randomized to and received BSC were censored on crossover.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  16. Efficacy: Event-free Probability of First Respiratory-related Hospitalization

    Probability of first-related hospitalization defined as any AE where the high-level group term contained the terms "respiratory" and the AE resulted in a hospitalization. Subjects randomized and received BSC were censored on crossover. Note: The hazard ratios for Belumosudil-R vs. BSC-NC and for Belumosudil-WC vs. BSC-NC were not calculable.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  17. Efficacy: Event-free Probability of Respiratory-related Death

    Probability of respiratory-related death, defined as any AE where the high-level group term contained the term "respiratory" and the AE resulted in a death. Subjects randomized to and who received BSC were censored on crossover.

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

  18. Efficacy: Mean Changes in SGRQ From Baseline at Weeks 24, 48 and 96

    The St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in subjects with obstructive airways disease consisting of 2 parts: (1) symptoms component (frequency \& severity) with a 3-month recall; and (2) activities that cause or are limited by breathlessness. Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Changes were assessed from baseline at Week 24, at Week 48, and at Week 96. The SGRQ scores range from 0 to 100, with higher scores indicating greater limitations. Based on empirical data and interviews with subjects, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change, and 12 units for very efficacious treatment

    Time frame: Up to 96 weeks (Weeks 24, 48, and 96)

07

Results

Posted Sep 8, 2022

Participant flow

Initial Treatment Period (24 Weeks)
Participant flow — Initial Treatment Period (24 Weeks)
MilestoneBelumosudil-RBSC-R
Started5224
Treated5124
Completed5118
Not completed16
Withdrew: Death01
Withdrew: Cross-overed before initial treatment period (24 weeks)05
Withdrew: Subject was randomized but did not receive treatment10
Post Switch Treatment Period (72 Weeks)
Participant flow — Post Switch Treatment Period (72 Weeks)
MilestoneBelumosudil-RBSC-R
Started5117
Completed233
Not completed2814
Withdrew: Death72
Withdrew: Lost to follow-up10
Withdrew: Other106
Withdrew: Withdrawal by subject106

Outcome measures

PrimaryEfficacy: Mean Changes in FVC From Baseline to Week 24

Changes in the mean Forced Vital Capacity (FVC) from baseline at Week 24. Normal FVC-- Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy females 20 to 60 years: 3.25 to 3.75 L

Time frame:
24 weeks
Reported as:
Mean · mL
Efficacy: Mean Changes in FVC From Baseline to Week 24
mLBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline2608.2 ± 829.62516.7 ± 741.82608.8 ± 840.42516.7 ± 741.82569.3 ± 794.3
At Week 242626.8 ± 886.92438.1 ± 757.12617.4 ± 890.82436.8 ± 784.52533.7 ± 832.7
Change at Week 24-115.8 ± 330.3-71.2 ± 254.2-110.8 ± 316.4-103.4 ± 225.0-99.5 ± 281.4
PrimaryEfficacy: Mean Changes in FVC% Predicted From Baseline at Week 24

Changes in the mean Forced Vital Capacity (FVC)% Predicted from baseline at Week 24. Normal FVC%: 80% to 120%

Time frame:
24 weeks
Reported as:
Mean · % of predicted
Efficacy: Mean Changes in FVC% Predicted From Baseline at Week 24
% of predictedBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline69.61 ± 18.0768.46 ± 15.6369.73 ± 17.7068.46 ± 15.6369.19 ± 16.71
At Week 2469.71 ± 19.2068.29 ± 13.4169.96 ± 18.4368.58 ± 13.9869.24 ± 16.25
Change at Week 24-2.82 ± 7.57-2.00 ± 7.36-2.66 ± 7.49-3.00 ± 6.41-2.58 ± 7.16
PrimarySafety: Percentages of Subjects With Non-serious TEAEs and Relationship to Study Treatment

Percentage of subjects with non-serious TEAEs by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Severity of TEAEs were measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 22.1 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal).

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil. Subjects randomized to BSC had the option of crossing over at 24 weeks.
Reported as:
Count of participants · Participants
Safety: Percentages of Subjects With Non-serious TEAEs and Relationship to Study Treatment
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
TEAEs Related to Treatment (All Grades)23932232
TEAEs Related to Treatment (Only Grades 3 & 4)20202
PrimarySafety: Percentages of Subjects With SAEs Related to Study Treatment

Percentage of subjects with serious TEAEs by relationship to treatment with belumosudil and/or BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil. Subjects randomized to BSC and crossing over also up to 24 weeks of BSC.
Reported as:
Count of participants · Participants
Safety: Percentages of Subjects With SAEs Related to Study Treatment
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Safety: Percentages of Subjects With SAEs Related to Study Treatment20202
PrimarySafety: Percentages of Subjects With TEAEs Leading to Discontinuation of Treatment With Belumosudil

Percentage of subjects with treatment-emergent adverse events (TEAEs) leading to subjects discontinuing from treatment. Investigators assessed whether TEAEs leading to discontinuation were related to study drug (possibly, probably, or definitely), belumosudil 400 mg PO QD.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil
Reported as:
Count of participants · Participants
Safety: Percentages of Subjects With TEAEs Leading to Discontinuation of Treatment With Belumosudil
ParticipantsBelumosudil-RBSC-RBelumosudil-WCTotal
All TEAEs Leading to Discontinuation1482222
TEAEs Related to Belumosudil Leading to Study Discontinuation5166
PrimarySafety: Percentages of Subjects With Deaths Related to Study Treatment

Percentage of subjects with deaths by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.

Time frame:
Up to 96 weeks (Weeks 24, 8, and 96) of treatment with belumosudil. Subjects randomized to BSC also had the option of crossing over to treatment with belumosudil at 24 weeks.
Reported as:
Count of participants · Participants
Safety: Percentages of Subjects With Deaths Related to Study Treatment
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Safety: Percentages of Subjects With Deaths Related to Study Treatment00000
SecondaryEfficacy: Mean Changes in FVC From Baseline at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--

Changes in the mean Forced Vital Capacities (FVC) at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. Normal FVC--Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy famles 20 to 60 years: 3.25 to 3.75 L GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I Index = 0 to 3 points * Stage II Index= 4 to 5 points * Stage III Index = 6 to 8 points

Time frame:
24 weeks
Reported as:
Geometric least squares mean · mL
Efficacy: Mean Changes in FVC From Baseline at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--
mLBelumosudil-WCBSC-NC
GAP Stage I-117.65 (-324.28 to 88.98)-156.50 (-355.39 to 42.40)
GAP Stage II-219.90 (-416.20 to -23.60)-179.94 (-444.35 to 84.47)
GAP Stage III101.95 (-1246.61 to 1450.50)7.79 (-1553.37 to 1568.95)
No Prior Use of Pirfenidone or Nintedanib-80.34 (-190.81 to 30.14)-46.21 (-167.93 to 75.51)
Statistical analysis
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.5733Results are not stable due to small sample size and signal/noise ratio
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.6967Results are not stable due to small sample size and signal/noise ratio
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.5003Results are not stable due to small sample size and signal/noise ratio
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.4866Results are not stable due to small sample size and signal/noise ratio
SecondaryEfficacy: Mean Changes in FVC From Baseline at Week 48, Week 96, and EOT

Changes in the mean Forced Vital Capacity (FVC) from baseline at Weeks 48 and 96, and End-of-Treatment (EOT) Normal FVC: Healthy males 20 to 60 years: 4.75 to 5.25 L; healthy females 20 to 60 years: 3.25 to 3.75 L

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Mean · mL
Efficacy: Mean Changes in FVC From Baseline at Week 48, Week 96, and EOT
mLBelumosudil-RBSC-RBelumosudil-WCTotal
Baseline2608.2 ± 829.62516.7 ± 741.82608.8 ± 840.42569.3 ± 794.3
Change at Week 48-197.2 ± 331.5-82.5 ± 329.7-199.6 ± 366.1-177.8 ± 358.8
Change at Week 96-141.0 ± 401.1-264.0 ± 896.0-122.2 ± 384.3-147.5 ± 492.3
Change at EOT-227.9 ± 367.7-110.7 ± 397.7-207.2 ± 353.7-180.9 ± 355.8
SecondaryEfficacy: Mean Change in Mean FEV1/FVC Ratio From Baseline at Weeks 24, 48, and 96 and EOT

Change in the mean ratio of Forced Expiratory Volume in 1 Second (FEV1) divided by the Forced Vital Capacity (FVC) at Week 24, Week 48, Week 96, and End-of-Treatment (EOT) Normal FEV1: 80% to 120% FEV1/FVC = Within 5% of predicted ratio

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Mean · Units
Efficacy: Mean Change in Mean FEV1/FVC Ratio From Baseline at Weeks 24, 48, and 96 and EOT
UnitsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline0.829 ± 0.06130.816 ± 0.06740.832 ± 0.05840.816 ± 0.06740.825 ± 0.0623
Change at Week 24-0.006 ± 0.04440.013 ± 0.0310-0.005 ± 0.04100.016 ± 0.03110.004 ± 0.0378
Change at Week 480.001 ± 0.0251-0.005 ± 0.0141-0.001 ± 0.0249—-0.002 ± 0.0232
Change at Week 96-0.012 ± 0.0420-0.014 ± 0.0378-0.012 ± 0.0402—-0.012 ± 0.0391
Change at EOT-0.010 ± 0.03620.011 ± 0.0372-0.011 ± 0.0453-0.010 ± 0-0.007 ± 0.0436
SecondaryEfficacy: Mean Changes in FVC% Predicted at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--

Changes in the mean Forced Vital Capacities (FVC)% Predicted at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I = 0 to 3 points * Stage II = 4 to 5 points * Stage III = 6 to 8 points

Time frame:
24 weeks
Reported as:
Geometric least squares mean · % of predicted
Efficacy: Mean Changes in FVC% Predicted at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--
% of predictedBelumosudil-WCBSC-NC
GAP Stage I-4.65 (-11.34 to 2.03)-6.53 (-13.14 to 0.07)
GAP Stage II-6.42 (-11.69 to -1.15)-4.69 (-11.58 to 2.19)
GAP Stage III2.34 (-36.32 to 40.99)-0.15 (-42.95 to 42.65)
Prior Use of Pirfenidone or Nintedanib-6.20 (-58.23 to 45.82)-14.91 (-92.49 to 62.68)
Statistical analysis
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.3391Results are not stable due to small sample size and signal/noise ratio
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.5201Results are not stable due to small sample size and signal/noise ratio
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.4426Results are not stable due to small sample size and signal/noise ratio
  • Belumosudil-WC vs BSC-NC · Mixed Models Analysis · p = 0.4260Results are not stable due to small sample size and signal/noise ratio
SecondaryEfficacy: Percentages of Subjects With Decrease ≥ 5% in FVC% Predicted From Baseline at Weeks 24, 48, and 96

Percentage of subjects exhibiting at least a 5% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Count of participants · Participants
Efficacy: Percentages of Subjects With Decrease ≥ 5% in FVC% Predicted From Baseline at Weeks 24, 48, and 96
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
At Week 24: Yes11714721
At Week 24: No2714321242
At Week 48: Yes14416—18
At Week 48: No15419—20
At Week 96: Yes626—8
At Week 96: No14317—17
SecondaryEfficacy: Percentage of Subjects With Decrease ≥ 10% in FVC% Predicted at Weeks 24, 48, and 96

Percentage of subjects who exhibited at least a 10% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Count of participants · Participants
Efficacy: Percentage of Subjects With Decrease ≥ 10% in FVC% Predicted at Weeks 24, 48, and 96
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
At Week 24: Yes546410
At Week 24: No3317401550
At Week 48: Yes719—10
At Week 48: No22726—30
At Week 96: Yes525—7
At Week 96: No15318—18
SecondaryEfficacy: Mean Change in 6MWD at Weeks 24, 48, and 96

The mean change in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, to Week 48, and to Week 96. Positive change = improvement; negative change = worsening

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Mean · meters
Efficacy: Mean Change in 6MWD at Weeks 24, 48, and 96
metersBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline368.59 ± 168.84349.25 ± 180.40350.12 ± 168.88323.11 ± 126.64345.17 ± 163.88
Change at Week 24-12.11 ± 101.78-16.60 ± 66.807.53 ± 177.88-0.77 ± 49.08-0.04 ± 140.22
Change at Week 48-18.33 ± 102.45119.00 ± 364.61-18.83 ± 95.33—6.23 ± 178.69
Change at Week 96-23.06 ± 78.84-47.80 ± 69.80-20.98 ± 72.80—-26.34 ± 71.60
SecondaryEfficacy: Percentages of Subjects With ≥ 50 Meter Improvement in 6MWD at Weeks 24, 48, and 96

The percentage of subjects who have at least a 50 meter improvement in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, Week 48, and Week 96.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Count of participants · Participants
Efficacy: Percentages of Subjects With ≥ 50 Meter Improvement in 6MWD at Weeks 24, 48, and 96
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
≥ 50 Meter Improvement at Week 24: Yes648211
≥ 50 Meter Improvement at Week 24: No3116371148
≥ 50 Meter Improvement at Week 48: Yes628—10
≥ 50 Meter Improvement at Week 48: No24628—32
≥ 50 Meter Improvement at Week 96: Yes525—7
≥ 50 Meter Improvement at Week 96: No12315—15
SecondaryEfficacy: Mean Changes in DLCO (%) at Weeks 24, 48, and 96

The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Mean · % of diffusing capacity of CO
Efficacy: Mean Changes in DLCO (%) at Weeks 24, 48, and 96
% of diffusing capacity of COBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline47.3 ± 11.747.3 ± 9.947.1 ± 12.048.0 ± 10.247.3 ± 11.1
Change at Week 24-2.7 ± 9.5-3.8 ± 5.4-3.1 ± 9.3-4.5 ± 5.6-3.6 ± 7.7
Change at Week 48-2.9 ± 8.3-7.1 ± 12.7-3.2 ± 8.0—-3.9 ± 9.0
Change at Week 96-4.2 ± 11.3-13.7 ± 17.7-6.0 ± 11.4—-8.2 ± 13.4
SecondaryEfficacy: Percentages of Subjects With Change From Baseline in DLCO (%) ≤ -15% at Weeks 24, 48, and 96

Percentage of the number of subjects who exhibit less than a -15% decrease in diffusing capacity of carbon monoxide (DLCO), measured as % from baseline at Week 24, Week 48, and Week 96 The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Count of participants · Participants
Efficacy: Percentages of Subjects With Change From Baseline in DLCO (%) ≤ -15% at Weeks 24, 48, and 96
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Week 24 Change ≤ -15%: Yes7710616
Week 24 Change ≤ -15%: No291433943
Week 48 Change ≤ -15%: Yes10411—14
Week 48 Change ≤ -15%: No18423—24
Week 96 Change ≤ -15%: Yes345—7
Week 96 Change ≤ -15%: No718—8
SecondaryEfficacy: Mean Changes in Total Lung Fibrosis Score, by HRCT, From Baseline at Weeks 24, 48, and 96

The change in Total Lung Fibrosis mean score from baseline at Weeks 24, 48, and 96. Measurements using quantitative high-resolution computerized tomography (HRCT) and include (1) extent of fibrotic abnormality; (2) fibrosis score; (3) ground glass opacity; (4) honeycombing score; (5) kurtosis of lung voxel intensity; (6) skewness of lung voxel intensity; (7) standard deviation of voxel; (8) CT total lung volume; (9) normal lung; (10) reticular score; and (11) evaluation of change on sequential scans. The Quantitative Lung Fibrosis (QLF) score measures the extent of reticular patterns with architectural distortion due to fibrosis using a support vector machine classifier. Range: 0 to 100. Higher scores imply greater impairment.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Mean · score on a scale
Efficacy: Mean Changes in Total Lung Fibrosis Score, by HRCT, From Baseline at Weeks 24, 48, and 96
score on a scaleBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline30.91 ± 14.5433.34 ± 17.8131.78 ± 15.4833.34 ± 17.8132.53 ± 16.45
Change at Week 247.36 ± 11.461.08 ± 6.318.00 ± 12.551.41 ± 6.314.67 ± 10.44
Change at Week 486.51 ± 11.766.23 ± 13.276.01 ± 11.74—6.06 ± 11.87
Change at Week 966.36 ± 10.418.47 ± 21.866.36 ± 10.41—6.71 ± 12.09
SecondaryEfficacy: Categorical Changes in Lung Fibrosis as Observed by Sequential Scans of Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96

The categorical changes of lung fibrosis using subjective visual assessments by radiologists from sequential scans at baseline, Week 24, Week 48, and Week 96. Changes were categorized as: (1) much better; (2) slightly better; (3) same; (4) slightly worse; and (5) much worse. This categorization is simplified as Better (Much or Slightly); Same; and Worse (Slightly or Much).

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Count of participants · Participants
Efficacy: Categorical Changes in Lung Fibrosis as Observed by Sequential Scans of Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96
ParticipantsBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Week 24: Better01111
Week 24: Same2213251135
Week 24: Worse13417417
Week 48: Better011—1
Week 48: Same616—7
Week 48: Worse10513—15
Week 96: Better01101
Week 96: Same10101
Week 96: Worse313—4
SecondaryEfficacy: Changes in Mean DTA Lung Fibrosis Score, by Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96

The change in Data-driven Texture Analysis (DTA) Lung Fibrosis mean score using sequential scans from Radiologist's Visual Reads from baseline to Weeks 24, 48, and 96. The change in DTA Lung Fibrosis mean score was measured using sequential scans from Radiologist's Visual Reads from baseline at Weeks 24, 48, and 96. DTA fibrosis score was computed as the number of Region of Interests (ROIs) classified as fibrotic divided by the total number of ROIs sampled from the lung segmentation volume. The DTA fibrosis score ranged from 0 - 100%, where higher scores indicated worsening of disease.

Time frame:
Up to 96 Weeks (Weeks 24, 48, and 96)
Reported as:
Mean · units on a scale (0-100)
Efficacy: Changes in Mean DTA Lung Fibrosis Score, by Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96
units on a scale (0-100)Belumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline23.1 ± 11.9922.7 ± 10.7722.3 ± 12.0722.7 ± 10.7722.5 ± 11.35
Change at Week 240.3 ± 4.820.6 ± 4.291.2 ± 6.860.6 ± 4.430.9 ± 5.70
Change at Week 483.1 ± 7.512.9 ± 4.882.9 ± 7.26—2.9 ± 6.44
Change at Week 967.5 ± 9.575.0 ± 7.077.5 ± 9.57—6.7 ± 8.16
SecondaryEfficacy: Event-free Probability of Acute Exacerbation of IPF

Acute exacerbation of IPF was defined by the following symptoms within 1 month that could not be explained by other reasons: (1) aggravated dyspnea; (2) newly discovered chest interstitial lung abnormality (by radiograph or HRCT); (3) SpO2 decrease to \< 88%. Acute exacerbation was diagnosed if Items #1 and #2 were present or if Items #1 and #3 were present and the following AEs did not occur: (A) any AE with the Preferred Term containing the word "infection" or "cardiac failure"; (B) pulmonary embolism; (C) pneumothorax.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Number · Event-free Probability
Efficacy: Event-free Probability of Acute Exacerbation of IPF
Event-free ProbabilityBelumosudil-RBelumosudil-WCBSC-NC
24 weeks0.91 (0.78 to 0.97)0.91 (0.80 to 0.96)0.92 (0.54 to 0.99)
48 weeks0.85 (0.70 to 0.93)0.84 (0.70 to 0.92)—
96 weeks0.64 (0.44 to 0.78)0.66 (0.48 to 0.79)—
Statistical analysis
  • Belumosudil-R vs BSC-NC · Log Rank · p = 0.8561
  • Belumosudil-WC vs BSC-NC · Log Rank · p = 0.8608
SecondaryEfficacy: Event-free Probability of Progression of IPF

Progression of IPF exacerbation was defined as the probability of a subject exhibiting IPF time from baseline to any of the following: (1) probability of first respiratory-related hospitalization; (2) probability of respiratory-related death; absolute decline in FVC% Predicted value of ≥ 10% vs. FVC %; probability of predicted value recorded at baseline; and (4) probability of absolute decline in DLCO, adjusted for hemoglobin (Hb), Percent of predicted value of ≥ 15% vs. DLCO at baseline. Subjects randomized to and received BSC were censored on crossover.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Number · Event-free Probability
Efficacy: Event-free Probability of Progression of IPF
Event-free ProbabilityBelumosudil-RBelumosudil-WCBSC-NC
24 weeks0.86 (0.71 to 0.93)0.80 (0.67 to 0.88)0.66 (0.39 to 0.83)
48 weeks0.52 (0.35 to 0.66)0.47 (0.33 to 0.60)—
96 weeks0.20 (0.09 to 0.35)0.16 (0.07 to 0.28)—
Statistical analysis
  • Belumosudil-R vs BSC-NC · Log Rank · p = 0.0084
  • Belumosudil-WC vs BSC-NC · Log Rank · p = 0.0508
SecondaryEfficacy: Event-free Probability of First Respiratory-related Hospitalization

Probability of first-related hospitalization defined as any AE where the high-level group term contained the terms "respiratory" and the AE resulted in a hospitalization. Subjects randomized and received BSC were censored on crossover. Note: The hazard ratios for Belumosudil-R vs. BSC-NC and for Belumosudil-WC vs. BSC-NC were not calculable.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Number · Event-free Probability
Efficacy: Event-free Probability of First Respiratory-related Hospitalization
Event-free ProbabilityBelumosudil-RBelumosudil-WC
24 weeks0.98 (0.85 to 1.00)0.96 (0.86 to 0.99)
48 weeks0.89 (0.74 to 0.96)0.85 (0.72 to 0.93)
96 weeks0.79 (0.61 to 0.90)0.75 (0.58 to 0.85)
SecondaryEfficacy: Event-free Probability of Respiratory-related Death

Probability of respiratory-related death, defined as any AE where the high-level group term contained the term "respiratory" and the AE resulted in a death. Subjects randomized to and who received BSC were censored on crossover.

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Number · Event-free Probability
Efficacy: Event-free Probability of Respiratory-related Death
Event-free ProbabilityBelumosudil-RBelumosudil-WCBSC-NC
24 weeks0.98 (0.85 to 1.00)0.98 (0.87 to 1.00)0.95 (0.69 to 0.99)
48 weeks0.92 (0.76 to 0.97)0.91 (0.77 to 0.97)—
96 weeks0.88 (0.71 to 0.95)0.88 (0.72 to 0.95)—
Statistical analysis
  • Belumosudil-R vs BSC-NC · Log Rank · p = 0.4251
  • Belumosudil-WC vs BSC-NC · Log Rank · p = 0.3294
SecondaryEfficacy: Mean Changes in SGRQ From Baseline at Weeks 24, 48 and 96

The St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in subjects with obstructive airways disease consisting of 2 parts: (1) symptoms component (frequency \& severity) with a 3-month recall; and (2) activities that cause or are limited by breathlessness. Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Changes were assessed from baseline at Week 24, at Week 48, and at Week 96. The SGRQ scores range from 0 to 100, with higher scores indicating greater limitations. Based on empirical data and interviews with subjects, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change, and 12 units for very efficacious treatment

Time frame:
Up to 96 weeks (Weeks 24, 48, and 96)
Reported as:
Mean · units on a scale
Efficacy: Mean Changes in SGRQ From Baseline at Weeks 24, 48 and 96
units on a scaleBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Baseline64.45 ± 18.9874.45 ± 18.9464.86 ± 18.2974.45 ± 18.9468.63 ± 18.83
Change at Week 24-5.78 ± 17.74-2.64 ± 9.59-2.63 ± 18.38-2.64 ± 9.59-2.64 ± 14.79
Change at Week 480.36 ± 15.342.07 ± 9.900.41 ± 14.63—0.63 ± 13.93
Change at Week 961.50 ± 16.619.35 ± 4.541.37 ± 15.76—2.60 ± 14.75

Adverse events

Collected over Subjects randomized to belumosudil 400 mg PO QD: up to 96 weeks of treatment Subjects randomized to BSC: 24 weeks of BSC plus up to 96 weeks of treatment with belumosudil 400 mg PO QD. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belumosudil-R7/51 (13.7%)29/51 (56.9%)50/51 (98%)
BSC-R3/24 (12.5%)10/24 (41.7%)23/24 (95.8%)
Belumosudil-WC9/68 (13.2%)38/68 (55.9%)67/68 (98.5%)
BSC-NC1/24 (4.2%)4/24 (16.7%)19/24 (79.2%)
Total10/75 (13.3%)39/75 (52%)73/75 (97.3%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
Acute respiratory failureRespiratory, thoracic and mediastinal disorders6/513/248/681/249/75
DyspneaRespiratory, thoracic and mediastinal disorders5/511/246/680/246/75
Acute myocardial infarction (AMI)Cardiac disorders1/512/242/681/243/75
Atrial fibrillationCardiac disorders1/512/243/680/243/75
PneumoniaInfections and infestations4/510/244/680/244/75
Congestive cardiac failureCardiac disorders3/510/243/680/243/75
Respiratory failureRespiratory, thoracic and mediastinal disorders1/511/242/680/242/75
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/511/241/680/241/75
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/511/241/680/241/75
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders0/511/241/680/241/75
Most frequent other events
Showing 10 of 125
Most frequent other events
EventBelumosudil-RBSC-RBelumosudil-WCBSC-NCTotal
DyspneaRespiratory, thoracic and mediastinal disorders19/515/2421/684/2424/75
CoughRespiratory, thoracic and mediastinal disorders14/518/2414/688/2422/75
DiarrheaGastrointestinal disorders12/516/2418/680/2418/75
Upper respiratory tract infectionInfections and infestations5/516/248/684/2411/75
Viral upper respiratory tract infectionInfections and infestations8/515/2411/682/2413/75
BronchitisInfections and infestations7/515/247/685/2412/75
NauseaGastrointestinal disorders6/514/248/683/2410/75
FatigueGeneral disorders7/514/2411/681/2411/75
Back painMusculoskeletal and connective tissue disorders5/514/247/682/249/75
Alanine aminotransferase (ALT) increasedInvestigations8/513/2410/681/2411/75

Baseline characteristics

One subject randomized to belumosudil 400 mg PO QD did not receive study medication. Analysis was performed using the safety population that consisted of all subjects who were randomized and received ≥ 1 dose of belumosudil-R or, for subjects who had BSC, week 1 assessments. Available data at baseline have been reported.

Age, Continuous
Age, Continuous(years)Belumosudil 400 mg PO QDBSC-RTotal
Mean72.5 ± 7.074.9 ± 5.973.3 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Belumosudil 400 mg PO QDBSC-RTotal
Female13619
Male381856
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belumosudil 400 mg PO QDBSC-RTotal
Hispanic or Latino606
Not Hispanic or Latino452469
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belumosudil 400 mg PO QDBSC-RTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White492473
More than one race000
Unknown or Not Reported000
Prior Use of Pirfenidone
Prior Use of Pirfenidone(Participants)Belumosudil 400 mg PO QDBSC-RTotal
Yes13417
No382058
Prior Use of Nintedanib
Prior Use of Nintedanib(Participants)Belumosudil 400 mg PO QDBSC-RTotal
Yes10414
No412061
Prior Use of Pirfenidone or Nintedanib
Prior Use of Pirfenidone or Nintedanib(Participants)Belumosudil 400 mg PO QDBSC-RTotal
Yes19625
No321850
GAP Stage
GAP Stage(Participants)Belumosudil 400 mg PO QDBSC-RTotal
Stage I11718
Stage II311243
Stage III9514

3 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • Pulmonary Associates, PA
    Phoenix, Arizona 85006, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • UC Davis Medical Center, Division of Pulmonary/CC/SM
    Sacramento, California 95817, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • Pulmonary Disease Specialists, PA, d/b/a PDS Research
    Kissimmee, Florida 34741, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • Piedmont Healthcare Pulmonary and Critical Care Research
    Austell, Georgia 30106, United States
  • Pulmonix, LLC
    Greensboro, North Carolina 27403, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Apr 2021, 58 months.

Results were first posted in Sep 2022, 1 year 4 months after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 58 months is above that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Feb 23, 2016
StartActual
May 26, 2016
Primary completionActual
Apr 13, 2021
CompletionActual
Apr 13, 2021
Results first posted
Sep 8, 2022
Last update
Sep 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02688647
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
May 26, 2016
Primary completion
Apr 13, 2021
Completion
Apr 13, 2021
Results posted
Sep 8, 2022
Last update
Sep 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion